BioVie Inc. (OTCMKTS: BIVI) Files An 8-K Other Events

BioVie Inc. (OTCMKTS: BIVI) Files An 8-K Other Events
Item 8.01 Other Events

Story continues below

On November 28, 2018, BioVie Inc. (“BioVie”) issued a press release announcing that the U.S. Food and Drug Administration had granted an Orphan Drug designation to Biovie for terlipressin for the treatment of hepatorenal syndrome. A copy of the press release is provided as Exhibit 99.1 to this Current Report.

(d) Exhibits

EX-99.1 2 biovie-20181128_8kex99z1.htm EXHIBIT 99.1 BioVie’s New Drug Candidate BIV201 Receives FDA Orphan Drug Designation for the Treatment of Hepatorenal Syndrome (HRS)   BioVie Inc. (OTCQB: BIVI) (“BioVie” or the “Company”),…
To view the full exhibit click here

An ad to help with our costs